APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.
Publication|Articles|December 8, 2023
- Pharmaceutical Commerce - December 2023
- Volume 18
- Issue 6
Pharmaceutical Commerce - December 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Commerce December 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Patients are the Priorityalmost 3 years ago
Brand Evolution and Engagementalmost 3 years ago
A Supply Chain Overhaulalmost 3 years ago
Continued Affordability Challenges in the Offingalmost 3 years ago
Who Moved My Prescription?almost 3 years ago
Transforming the Patient Hub into a Hub of Patient Centricityalmost 3 years ago
Navigating the Biosimilars Marketplacealmost 3 years ago
An Outlook on Data-Powered Patient Supportalmost 3 years ago
Prescribing Resilience: Third-Party Risks and Pharmaabout 3 years ago
The Business Case for RWEAdvertisement
Related to this article
How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.
Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
Advertisement
Advertisement